What's atypical about atypical antipsychotic drugs?

Current Opinion in Pharmacology

Volumn 4, Issue 1, 2004, Pages 53-57

  Meltzer, Herbert Y ^a  

^a Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BLONANSERIN; BUTACLAMOL; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; FLUPHENAZINE; HALOPERIDOL; ILOPERIDONE; LEVODOPA; MELPERONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; PERPHENAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE;

ACETYLCHOLINE RELEASE; ARTICLE; BRAIN CORTEX; CARDIOVASCULAR DISEASE; CELL SURVIVAL; COGNITION; DELUSION; DIABETES MELLITUS; DOPAMINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; METABOLIC DISORDER; NERVE CELL; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; OPISTHOTONUS; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; SIDE EFFECT; SUICIDE; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 0742271350     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.09.010     Document Type: Review

References (41)

1. Creese I. Burt D.R. Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 192 1976 481-483
2. Seeman P. Lee T. Chau-Wong M. Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors Nature 261 1976 717-719
3. Burris K.D. Molski T.F. Xu C. Ryan E. Tottori K. Kikuchi T. Yocca F.D. Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 2002 381-389
4. Oka M. Noda Y. Ochi Y. Furukawa K. Une T. Kurumiya S. Hino K. Karasawa T. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties J Pharmacol Exp Ther 264 1993 158-165
5. Pani L. Gessa G.L. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia Mol Psychiatry 7 2002 247-253
6. Sokoloff P. Diaz J. Levesque D. Pilon C. Dimitriadou V. Griffon N. Lammers C.H. Martres M.P. Schwartz J.C. Novel dopamine receptor subtypes as targets for antipsychotic drugs Ann N Y Acad Sci 757 1995 278-292
7. Lacroix L.P. Hows M.E.P. Shah A.J. Hagan J.J. Heidbreder C.A. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex Neuropsychopharmacology 28 2003 839-849
8. Jardemark K. Wadenberg M.L. Grillner P. Svensson T.H. Dopamine D3 and D4 receptor antagonists in the treatment of schizophrenia Curr Opin Investig Drugs 3 2002 101-105
9. Kapur S. Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient Biol Psychiatry 50 2001 873-883
10. Marcus M.M. Malmerflt A. Nyberg S. Svensson T.H. Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses Eur Neuropsychopharmacol 12 2002 379-386
11. D'Souza C. Gupta A. Alldrick M.D. Sastry B.S. Management of psychosis in Parkinson's disease Int J Clin Pract 57 2003 295-300
12. Andersson C. Hamer R.M. Lawler C.P. Mailman R.B. Lieberman J.A. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs Neuropsychopharmacology 27 2002 143-151
13. Davis J.M. Chen N. Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 2003 553-564
14. Tuunainen A. Wahlbeck K. Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials Schizophr Res 56 2002 1-10
15. Geddes J. Freemantle N. Harrison P. Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 321 2000 1371-1376
16. Leucht S. Wahlbeck K. Hamann J. Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 361 2003 1581-1589
17. Meltzer H.Y. Alphs L. Green Al. Altamura A.C. Anand R. Be rtoldi A. Bourgeois M. Chouinard G. Islam M.Z. Kane J. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry 60 2003 82-91
18. Hagger C. Buckley P. Kenny J.T. Friedman L. Ubogy D. Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine Biol Psychiatry 34 1993 702-712
19. Harvey P. Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment Am J Psychiatry 158 2001 176-184
20. Baptista T. Kin N.M. Beaulieu S. de Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives Pharmacopsychiatry 35 2002 205-219
21. Meltzer H.Y. Davidson M. Glassman A.H. Vieweg W.V. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment J Clin Psychiatry 63Suppl 9 2002 25-29
22. Kroeze W.K. Hufeisen S.J. Popadak B.A. Renock S.M. Steinberg S. Ernsberger P. Jayathilake K. Meltzer H.Y. Roth B.L. H1-histamine receptor affinity redicts short-term weight gain for typical and atypical antipsychotic drugs Neuropsychopharmacology 28 2003 519-526
23. Meltzer H.Y. Cola P.A. Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment Neuropsychopharmacology 15 1996 395-405
24. Meltzer H.Y. Matsubara S. Lee J.-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J Pharmacol Exp Ther 251 1989 238-246
25. Westerink B.H.C. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol 455 2002 1-18
26. Kapur S. Zipursky R.B. Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia Am J Psychiatry 156 1999 286-293
27. Xiberas X. Martinot J.L. Mallet L. Artiges E. Loc'H C. Maziere B. Paillere-Martinot M.L. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia Br J Psychiatry 179 2001 503-508
28. 123I]-epidepride SPET study J Clin Psychopharmacol 23 2003 5-14
29. Kuroki T. Meltzer H.Y. Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens J Pharmacol Exp Ther 288 1999 774-781
30. Liegeois J. Ichikawa J. Meltzer H.Y. 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner Brain Res 947 2002 157-165
31. Ichikawa J. Ishii H. Bonaccorso S. Fowler W.L. O'Laughlin I.A. Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J Neurochem 76 2001 1521-1531
32. Ichikawa J. Dai J. O'Laughlin I.A. Fowler W.L. Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum Neuropsychopharmacology 26 2002 325-339
33. Duncan G.E. Miyamoto S. Lieberman J.A. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation J Pharmacol Exp Ther 305 2003 999-1005
34. Hanaoka T. Toyoda H. Mizuno T. Kikuyama H. Morimoto K. Takahata R. Matsumura H. Yoneda H. Alterations in NMDA receptor subunit levels in the brain regions of rats chronically administered typical or atypical antipsychotic drugs Neurochem Res 28 2003 919-924
35. Polese D. de Serpis A.A. Ambesi-Impiombato A. Muscettola G. de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of d-cycloserine Neuropsychopharmacology 27 2002 906-913
36. Cochran S.M. McKerchar C.E. Morris B.J. Pratt J.A. Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol Neuropharmacology 43 2002 394-407
37. Ninan I. Jardemark K.E. Wang R.Y. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-d-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex Neuropharmacology 44 2003 462-472
38. Varvel S.A. Vann R.E. Wise L.E. Philibin S.D. Effects of antipsychotic drugs on operant responding after acute and repeated administration Psychopharmacology (Berl) 160 2002 182-191
39. Kumar R. Palit G. Dhawan B.N. Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey Eur J Pharmacol 462 2003 133-138
40. Bai O. Chlan-Fourney J. Bowen R. Keegan D. Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs J Neurosci Res 71 2003 127-131
41. +-induced apoptosis Eur J Neurosci 17 2003 1563-1570